Qdem Pharmaceuticals Limited, launched in the UK last month, now markets a generic prolonged release oxycodone tablet, branded Longtec®.
Longtec tablets are licensed for moderate to severe pain in patients with cancer or post-operative pain or severe pain requiring the use of a strong opioid. Oxycodone is a strong opioid analgesic similar to morphine that has been in use orally for over 10 years in the UK.
This is Qdem’s first product, but the company plans to add to their portfolio and will consider products outside of pain management. Matthew Homent, Head of Commercial said, “Our vision is to support our healthcare customers in delivering high-quality patient care in a value-driven environment and this applies across all therapeutic areas. We want to work with manufacturers that match our high standards of customer service, as well as delivering on our promises of quality, value and reliability.”
Supplies of prolonged release oxycodone tablets will come from Bard Pharmaceuticals Limited, the Production & Supply Chain business of the Napp Pharmaceutical Group. Bard is a UK manufacturer with significant expertise in the manufacture and supply of prolonged release products, and a strong track record in providing a reliable supply of medicines to UK customers.
Matthew added, “We understand that the NHS needs to derive value from all its purchasing decisions, but that in doing so there must be no compromise on the quality of patient care. At Qdem, we will look to support our healthcare customers in achieving this balance when they purchase their medicines.”